Vivex Biomedical Raised $6.6MM in Series A Funding
Vivex Biomedical raised US $6.6MM of a potential $10MM offering of Series A Convertible Preferred Stock. Jan 06, 2016
NuVasive to Acquire Ellipse Technologies
NuVasive entered into a definitive agreement to acquire Ellipse Technologies for US $380MM in cash, with a potential $30MM milestone payable in 2017. The transaction is slated to close in mid-1Q16. Ellipse posted 2015 revenue of ~$40MM, +54% vs. 2014. Jan 05, 2016
First Spinal Fusion with Single-Step Insertion of DSG Technology-Enabled Screws
SpineGuard announced the world’s 1st spinal fusion procedure performed with 1-step insertion of pedicle screws guided by Dynamic Surgical Guidance or DSG™ technology. Jan 05, 2016
Agent Medical Launches ArthroBridge and ArthroMate Lower Extremity Products
Agent Medical launched ArthroBridgeâ„¢, an implant for the treatment of hammertoes, and the ArthroMateâ„¢ rasp designed for rear foot fusion procedures. Jan 05, 2016
Bone Therapeutics Granted Additional EUR 2MM in Funding
Bone Therapeutics was granted an additional 2MM (~US $2.15MM) in non-dilutive funding, bringing the total non-dilutive funding received within 2015 to 5MM. Jan 05, 2016
Smith+Nephew Completes Acquisition of Blue Belt Technologies
Smith+Nephew completed its acquisition of Blue Belt Technologies, developer of the Navio surgical robotics-assistance system for unicondylar knee replacement. Jan 05, 2016
Ortho Kinematics Raises $4 Million in Debt Financing
Ortho Kinematics closed US $4MM in debt financing. Funds will support global commercialization of the Vertebral Motion Analysis product for radiographic assessment of spinal motion and instability, as well as launch of new product features. Jan 05, 2016
Bioventus Launches Durolane OA Treatment in Taiwan
Bioventus launched DUROLANE® single-injection hyaluronic acid-based osteoarthritis treatment in Taiwan. Jan 04, 2016
Vericel Submits BLA to FDA for MACI for Treatment of Knee Cartilage Defects
Vericel submitted a Biologics License Application to FDA for MACIâ„¢ matrix applied characterized autologous cultured chondrocytes, an investigational product intended to treat adult symptomatic cartilage defects of the knee. Jan 04, 2016
Extremities Market Attracts New Players and Innovation
The extremities market generated worldwide product sales of $6.7 billion in 2014, a 9.5% year-over-year increase driven by the absence of payor scrutiny and company saturation, as well as heightened interest from surgeons and patients, according to ORTHOWORLD estimates. Oct 01, 2015
